Sarepta Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $14.77
- 52-Week Range
- $14.53 – $24.68
- Market Cap
- $1.56B
- P/E (TTM)
- 726.50
- EPS (TTM)
- 0.02
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.02
- PEG Ratio
- -0.09
- Return on Equity
- -8.05%
- Return on Assets
- -0.16%
- Gross Margin
- 23.40%
- Operating Margin
- -0.43%
- Profit Margin
- -5.86%
- Current Ratio
- 3.46
- Debt/Equity
- 0.71
- Total Debt
- $1.08B
- Free Cash Flow
- $109.31M
- Revenue Growth
- -4.50%
- Earnings Growth
- —
- Enterprise Value
- $1.76B
Market Snapshot
About
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on precision genetic medicine for rare diseases. The company develops RNA-targeted therapeutics and gene therapy candidates, particularly for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies. It has multiple approved treatments and a robust pipeline of investigational therapies.